Beyond Outreach. Inside the U.S. Market.
European innovation meets U.S. clinical authority. We move beyond “advisory” by placing clinician-investors at the heart of your strategy as principals. Direct access. No cold starts.
01 IC memos in 10 days
02 U.S. KOLs in 90 days
03 Non-dilutive funding mapped
- Silicon Valley
- Europe
- Israel
Your U.S. Clinical Front Office.
An elite advisory for European medtech founders and the VCs who back them. High-stakes strategy, signed by the clinicians who know the market best. We integrate named U.S. Clinician-Investors into every engagement. As LPs in our affiliated fund, our advisors are more than consultants — they are stakeholders who sign diligence memos as Principals.
01
Clinicians sign as principals.
They are LPs in our affiliated fund. They sign diligence memos with their own names on the line. Not retained advisors, not retainer hours — principals.
02
Silicon Valley access, day one.
A 2,000-clinician U.S. network anchors every engagement. The room European medtech founders need to be in — opened the day the work starts.
03
Non-dilutive runway included.
Horizon Europe, EIT Health, EIC, BIRD, and national programmes mapped alongside every paid scope. Built in, never a side offer.
Four Segments.
Any European medtech or digital health company ready to engage the U.S. Same Discovery Call, same scope conversation, same engagement options — regardless of stage or country.
01
European Funded Startups
Medtech & Digital Health · Ready for the U.S.
We open the U.S. KOL and reference-site doors that don't open from cold outreach at all — in 90 days, with U.S. clinician sign-off on the regulatory pathway narrative your investors will demand, and non-dilutive funding mapped alongside.
- 3–5 U.S. KOL conversations in your subspecialty
- Clinical reference site introductions toward pilot
- 25–35 prioritized U.S. funds with warm-intro sequencing
02
European VCs & Family Offices
Healthtech-Focused Investors
We replace your fragmented network of academic advisors with a single credentialed source — U.S. clinicians who are LPs in our affiliated fund and sign memos as named principals — cutting time from CIM to pass/no-pass from 4–6 weeks to 10 days.
- IC-grade memos on single targets, 10-day turnaround
- Standing retainer for 4–8 deals per year
- U.S. co-investor introductions for portfolio companies
03
Service Providers
Build Partners · CROs · Regulatory Firms
Hand us a one-page memo describing your ideal U.S. customer — we build the warm-introduction path through the clinician-investor network, so you stop starting every enterprise sales cycle from cold.
- 8–16 warm enterprise introductions per year
- Pre-vetted SOW templates that close 2–3× faster
- Joint thought leadership and named co-branding
04
Corporates
Pharma · Payors · Hospital Groups
We help your innovation team ship one clinically-defensible AI or digital-health deployment under EU AI Act, MDR, and IVDR — at one-quarter the cost of Big-3 advisors, with the named clinician sign-off your board will accept.
- Deployment design with clinician sign-off as principal
- Full EU AI Act / MDR / IVDR review, board-ready
- Curated quarterly pipeline of vetted European startup partners
Six engagements.
Every relationship begins with a free Discovery Call. Lite, Standard, and Premium tiers across most engagements — scope shaped to your situation. Pricing is transparent on request.
01
Discovery Call & Entry Products
Any segment · Free or scoped, paid in days
30 min — 4 weeks
Diagnose the U.S. gap in 30 minutes, at zero cost. If the conversation surfaces a specific decision worth a scoped step, three entry products close in days.
Discovery Call.
30–60 minutes. Written 1-page summary in 48 hours with scope recommendation. No commitment.
Written Brief.
5-page async deliverable answering one scoped question. One week. No live call.
Team Briefing.
2-hour live workshop with your team plus 8-page briefing pack. Up to 10 attendees.
Warm Intros.
8–10 curated introductions to U.S. clinicians, investors, or operators. Each double-opted-in before delivery. Four weeks.
02
30-Day U.S. Strategy Memo
Funded Startups · Strategic diagnostic and on-ramp
14 — 30 days
Replace a four-month internal U.S. strategy review with a 30-day diagnostic, an explicit on-ramp memo, and a clinician-co-presented read-out.
Strategic diagnostic: U.S. fit, regulatory posture, commercial gap
Stakeholder mapping: KOLs, investors, reference-site candidates, partners
Three-action quick-win shortlist, ready to execute in the next 30 days
On-ramp memo: recommended next engagement, scope, sequencing
Premium tier adds clinician partner co-presenting the read-out, two warm introductions delivered during the engagement, and a 60-day check-in
03
U.S. Market Entry
Funded Startups · Cross-border execution
3 / 6 / 12 months
Open the U.S. clinical and capital doors that don't open from cold outreach at all — in 90 days, with U.S. clinician sign-off on the regulatory pathway narrative your investors will demand.
3-Month U.S. Validation.
Narrative repositioning, 5 KOL conversations, 25–35 fund investor map, go/no-go memo at month 3.
6-Month U.S. Market Entry.
Full narrative + KOL bench + three reference-site conversations + warm-intro sequenced investor universe + month-3 progress review + regulatory pathway opinion.
12-Month U.S. Market Entry + Round Support.
Full six-month scope, dedicated named clinician partner, month-6 in-target-market convening, round-positioning support, U.S. co-investor introductions, non-dilutive funding mapping for the next two cycles.
04
Clinical Due Diligence
VCs & Family Offices · IC-grade memos, optionally clinician co-signed
10 days — 12 months
IC-grade memos co-signed by named U.S. clinician-investors — cutting time from CIM to pass/no-pass from 4–6 weeks to 10 days, at a fraction of the cost of cobbling together academic advisors at €200–500 per hour.
Single Screen.
10-day IC-grade memo on a single target: clinical evidence review, regulatory pathway opinion (FDA + EU + national), top three risks. Senior clinician partner reviews.
Standing Retainer (Standard).
6-month: four deals, full IC memos, clinician review.
Standing Retainer (Premium).
12-month: eight deals, clinician co-signs as named principal on every memo.
Standing Retainer (Portfolio).
Quarterly portfolio reviews, on-call clinician access, U.S. pilot brokerage, regulatory monitoring, U.S. co-investor introductions, non-dilutive funding briefing, named-partner role.
05
Clinically-Defensible Deployment
Corporates · One shipped AI / digital-health initiative
3 / 6 / 12 months
Ship one clinically-defensible AI or digital-health deployment under EU AI Act, MDR, and IVDR — at one-quarter the cost of Big-3 advisors, with the named clinician sign-off your board will accept.
Deployment design with named GHIN clinician sign-off as principal on clinical defensibility
Full EU AI Act / MDR / IVDR coverage from Sojo’s security and compliance practice
Board-ready materials covering clinical posture and regulatory posture
Curated quarterly pipeline of clinically-vetted European medtech startup partners
12-month tier adds non-dilutive co-funding opportunity mapping where the corporate can co-apply as deployment partner
06
Business Development as a Service
Service Providers · Warm-intro pipeline into U.S. enterprise
6 / 12 months & beyond
You give us a one-page target-customer memo. We map your list against the clinician-investor network, open warm doors that don't open without clinical-grade brand association, and you close the deals.
Listing.
Directory listing in the GHIN preferred-partner network, single pre-vetted SOW template, brand association. 12-month commitment.
Active.
8 warm enterprise introductions per year, three pre-vetted SOW templates, joint thought leadership, active joint go-to-market. 6-month initial commitment.
Co-Branded.
Full Active scope plus named co-branding, 16+ warm introductions per year, co-published thought leadership, flexible economics. 12 months and beyond.
Anchored in Silicon Valley medtech innovation.
The Global Health Impact Network is the U.S. clinician-investor community that anchors every engagement we run. Founded by Gary Goldman, headquartered in California. Structurally different from any clinical-advisor model the buyer has seen before.
2,000+
Clinician-Investors
A network, not a roster.
Two thousand-plus clinicians across forty specialties. Cardiology, behavioral health, oncology, gastroenterology, endocrinology, pediatrics, primary care, and digital-health-adjacent specialties (radiology, pathology, anesthesia) are deepest.
LP.
In The Fund
Skin in the game, not retainers.
The clinicians are limited partners in the affiliated fund, not retained advisors. They co-invest. They sign diligence memos as named principals. This is what carries the weight inside an investment committee.
40.
Specialties Live
Sourced per engagement.
A dedicated GHIN Analyst maps the bench to your specific target deal or programme. We name the clinician partner before scope sign-off — not after.
Founded by Gary Goldman, DDS, MD — physician, healthcare innovator, and the architect of the clinician-investor model that defines the network.
Two named leads.
Europe
Wojciech (Voytek) Majewski
Voytek leads the firm's European presence across client engagements and ecosystem partnerships. His work spans transatlantic medtech advisory, U.S. market entry, and non-dilutive funding strategy for European medtech founders. Sojo.consulting is the broader Silicon Valley-fluent operator and engineering practice he founded.
United States
Gary Goldman, DDS, MD
Gary brings a rare multidisciplinary background — clinical medicine, anesthesiology, healthcare informatics, entrepreneurship, and executive leadership. He founded the Global Health Impact Network to close the gap between frontline clinical insight and healthcare innovation, building a community where physicians serve not only as care providers but as investors, advisors, and co-creators of the technologies defining the next era of healthcare. His vision elevates clinician-led investment as a force multiplier — accelerating impactful companies while keeping new technologies grounded in real-world patient and provider needs.
California·DDS·MD
Start with a free Discovery Call.
One 30–60 minute conversation. Written 1-page summary in 48 hours with a scope recommendation. No follow-on commitment.
Silicon Valley·Europe·Israel
Navigate
© 2026 Sojo.consulting LLC. All rights reserved.
Silicon Valley·Europe·Israel